This inventor holds 1 USPTO granted patent. Top assignee: Ssp Co. Ltd. Active years: 2000.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2000
Title: The Innovations of Yoshihisa Sada
Introduction
Yoshihisa Sada is a notable inventor based in Narita, Japan. He has made significant contributions to the field of pharmaceuticals, particularly through his innovative work on substituted quinolone derivatives. His research has led to advancements in anti-ulcer medications, showcasing his commitment to improving healthcare.
Latest Patents
Yoshihisa Sada holds a patent for "Substituted quinolone derivatives and pharmaceuticals containing the same." This patent describes substituted quinolone derivatives represented by a specific formula, where R¹ represents a substituted or unsubstituted (hetero)aryl group, R² represents H or an alkoxycarbonyl, substituted aminocarbonyl, cyano or similar group, and R³ and R⁴ each independently represent H or a substituted alkyl, aryl, amino or similar group, along with their salts. These derivatives and their salts exhibit excellent anti-ulcer activities, highlighting their potential therapeutic benefits.
Career Highlights
Yoshihisa Sada is associated with Ssp Co. Ltd., where he continues to develop innovative pharmaceutical solutions. His work has not only contributed to the scientific community but has also had a positive impact on patient care through the development of effective medications.
Collaborations
Yoshihisa has collaborated with notable colleagues, including Haruyoshi Honda and Norimitsu Umehara. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.
Conclusion
Yoshihisa Sada's contributions to the field of pharmaceuticals through his patented innovations demonstrate his dedication to advancing medical science. His work on substituted quinolone derivatives is a testament to the importance of research and collaboration in developing effective treatments.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile